1[1]Kearns GL,Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med, 2003, 349 (12): 1157 ～1167
2[2]Ittmann PI,Amamath R, Berseth CL.Maturation: of antroduodenal motor activity in preterm and term infants. Dig Dis Sci,1992, 37 (1): 14～19
3[3]Leeder JS, Kearns GL. The challenges of delivering pharmacogenomics into clinical pediatrics. Pharmacogenomics J,2002,2:141 ～ 143
4[4]Alcom J, McNamara PJ. Ontogeny of hepatic and renal systemic clearance pathways in infants. Clin Pharmacokinet, 2002, 41:1077 ～ 1094
5[5]Steinbrook R. Testing medications in children. N Engl J Med,2002, 347: 1462～1470
6[6]Novel mechanisms of action of three antiepileptic drugs, vigabatrin,tiagabine,and topiramate. Neurochem Res,2003,28 (2):333 ～ 340
7[7]Alva Moncayo E, Ruiz Ruiz A.The value of topiramate used with conventional schemes as an adjunctive therapy in the treatment of Lennox Gastaut syndrome. Rev Neurol, 2003, 36 (5): 453 ～ 457
8[8]Martina Bebin MD. Pediatric partial and partial and genetalized seizures. J Child Neurol, 2002, 17 (Suppl.): S65 ～ S69
9[9]Cross JH. Topiramate monotherapy for childhood absence seizures:an open label pilot study. Seizure, 2002, 11 (6): 406 ～ 410
10[10]Tatum WO, French JA, Faught E, et al. The PADS Investigators. Postmarketing experience with topiramate and cognition.Epilepsia, 2001, 42 (9): 1134～1140
